Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0033377 (
prolapse
)
11,717
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
DNA2
encodes a protein with nuclease, ATPase, and helicase domains, and serves to maintain mitochondrial DNA integrity. Mutations in
DNA2
cause autosomal dominant progressive ophthalmoplegia with mitochondrial DNA deletions. This disorder was first reported in four patients with heterozygous, missense mutations in
DNA2
. Clinical symptoms include limb-girdle and lower extremity weakness, myalgia, and ophthalmoplegia. All had a slowly progressive disease course and did not present for clinical evaluation until the fifth or sixth decade. We report a case of congenital-onset myopathy and
ptosis
in a child who was found to have a novel
DNA2
variant resulting in a premature termination codon (p.Asn568Ilefs*4). Only one other case of a truncating mutation in
DNA2
has been reported, and that patient also had early-onset, severe disease. We hypothesize that haploinsufficiency for the
DNA2 protein
due to truncating mutations results in mitochondrial genome instability and clinical symptoms of early-onset myopathy. Missense mutations that allow for residual protein function lead to a milder clinical phenotype.
...
PMID:Novel truncating variant in DNA2-related congenital onset myopathy and ptosis suggests genotype-phenotype correlation. 2855 58
Objectives:
To report two novel
DNA2
gene mutations causing early onset myopathy with cardiac involvement and late onset mitochondriopathy with rhabdomyolysis.
Methods:
We performed detailed clinical, muscle histopathology and molecular studies including mitochondrial gene NGS analysis in two patients (Patient 1 and 2), a mother and her son, belonging to a Mexican family, and a third sporadic French patient.
Results:
Patient 1 and 2 presented with an early onset myopathy associated with
ptosis
, velopharyngeal weakness, and cardiac involvement. Patient 3 presented rhabdomyolysis unmasking a mitochondrial disease characterized by a sensorineural hearing loss,
ptosis
, and lipomas. Muscle biopsies performed in all patients showed variable mitochondrial alterations. Patient 3 had multiple mtDNA deletion in his muscle. Genetic studies revealed a novel heterozygous frameshift mutation in
DNA2
gene (c.2346delT p.Phe782Leufs
*
3) in P1 and P2, and a novel heterozygous missense mutation in
DNA2
gene (c.578T>C p.Leu193Ser) in the P3.
Conclusions:
To date only few AD cases presenting either missense or truncating
DNA2
variants have been reported. None of them presented with a cardiac involvement or rhabdomyolysis. Here we enlarge the genetic and phenotypic spectrum of
DNA2
-related mitochondrial disorders.
...
PMID:Novel Phenotypes and Cardiac Involvement Associated With DNA2 Genetic Variants. 3163